Nvidia and Eli Lilly Plan $1 Billion AI Drug Discovery Lab
Nvidia Corp and Eli Lilly and Co are partnering on a roughly $1 billion artificial intelligence drug discovery lab in San Francisco. The facility will combine Nvidia's computing infrastructure with Eli Lilly's proprietary pharmaceutical data to accelerate compound testing and clinical failure analysis.
Eli Lilly CEO Dave Ricks highlighted the partnership's data advantage, noting that while many tech-bio competitors train their models on publicly available datasets of roughly 4,000 approved drugs, Eli Lilly has access to data from 3 million drugs that failed during development. This dataset is intended to help AI systems better predict clinical trial failures and refine drug design before human testing.
From the sources (2 posts)
@bearlyaiNvidia and Eli Lilly are building a $1B lab for AI drug discovery in SF. Lilly CEO Dave Ricks talks about their data advantage: “Some scale [tech-bio] players…are just training on public data but they’re only 4,000 ever approved drugs. Lil
@trungtphanRT @bearlyai: Nvidia and Eli Lilly are building a $1B lab for AI drug discovery in SF. Lilly CEO Dave Ricks talks about their data advanta…